Hair Repigmentation During Immunotherapy Treatment With an Anti–Programmed Cell Death 1 and Anti–Programmed Cell Death Ligand 1 Agent for Lung Cancer
Sign Up to like & getrecommendations! Published in 2017 at "JAMA Dermatology"
DOI: 10.1001/jamadermatol.2017.2106
Abstract: Importance New targeted therapies for cancer have been released in recent years, opening new horizons in the treatment of patients with cancer. However, their related adverse events (AE) are not fully characterized. Hair repigmentation (HR)… read more here.
Keywords: hair repigmentation; treatment; anti; programmed cell ... See more keywords
Association of Cutaneous Immune-Related Adverse Events With Increased Survival in Patients Treated With Anti-Programmed Cell Death 1 and Anti-Programmed Cell Death Ligand 1 Therapy.
Sign Up to like & getrecommendations! Published in 2022 at "JAMA dermatology"
DOI: 10.1001/jamadermatol.2021.5476
Abstract: Importance Despite the efficacy of immune checkpoint inhibitors (ICIs), cutaneous immune-related adverse events (cirAEs) occur in 20% to 40% of all treated patients. To our knowledge, little is known about the predictive value of these… read more here.
Keywords: cell death; therapy; programmed cell; anti programmed ... See more keywords
Neurological Complications Associated With Anti–Programmed Death 1 (PD-1) Antibodies
Sign Up to like & getrecommendations! Published in 2017 at "JAMA Neurology"
DOI: 10.1001/jamaneurol.2017.1912
Abstract: Importance Neurological complications are an increasingly recognized consequence of the use of anti–programmed death 1 (PD-1) antibodies in the treatment of solid-organ tumors, with an estimated frequency of 4.2%. To date, the clinical spectrum and… read more here.
Keywords: anti therapy; treatment; neurological complications; associated anti ... See more keywords
Effectiveness and safety of lenvatinib plus anti‐programmed death‐1 antibodies in patients with hepatocellular carcinoma: A real‐world cohort study
Sign Up to like & getrecommendations! Published in 2023 at "Cancer Medicine"
DOI: 10.1002/cam4.5661
Abstract: Lenvatinib plus anti‐programmed death‐1 (anti‐PD‐1) antibody combinations have shown potent anti‐tumor effect in phase I/II trials in advanced or unresectable hepatocellular carcinoma (HCC), but real‐world data are limited. read more here.
Keywords: hepatocellular carcinoma; plus anti; programmed death; anti programmed ... See more keywords
Circulating MicroRNAs and Extracellular Vesicle–Containing MicroRNAs as Response Biomarkers of Anti–programmed Cell Death Protein 1 or Programmed Death-Ligand 1 Therapy in NSCLC
Sign Up to like & getrecommendations! Published in 2020 at "Journal of Thoracic Oncology"
DOI: 10.1016/j.jtho.2020.05.022
Abstract: Abstract Introduction Anti–programmed cell death protein 1 (PD-1) or programmed death-ligand 1 (PD-L1) antibody therapy is a standard treatment for advanced NSCLC, and PD-L1 immunohistochemistry is used as a predictive biomarker for therapeutic response. However,… read more here.
Keywords: cell death; response; programmed cell; death ... See more keywords
New-onset third-degree atrioventricular block because of autoimmune-induced myositis under treatment with anti-programmed cell death-1 (nivolumab) for metastatic melanoma
Sign Up to like & getrecommendations! Published in 2017 at "Melanoma Research"
DOI: 10.1097/cmr.0000000000000314
Abstract: There has been considerable progress in treating malignant melanoma over the last few years. The immune-checkpoint-inhibitors nivolumab and pembrolizumab have been approved by the Food and Drug Administration in 2014 for the therapy of metastatic… read more here.
Keywords: melanoma; third degree; programmed cell; cell death ... See more keywords
Bullous pemphigoid associated with anti‐programmed cell death protein 1 and anti‐programmed cell death ligand 1 therapy: A case series of 13 patients
Sign Up to like & getrecommendations! Published in 2022 at "Australasian Journal of Dermatology"
DOI: 10.1111/ajd.13960
Abstract: We present a case series of 13 patients, the first Australian single‐centre study of bullous pemphigoid (BP) associated with immune checkpoint inhibitors (ICI): cytotoxic T‐lymphocyte antigen (CTLA4) and programmed cell death receptor (PD1) inhibitors. All… read more here.
Keywords: cell death; programmed cell; anti programmed; case series ... See more keywords
Enhanced stimulation of antigen‐specific immune responses against nucleophosmin 1 mutated acute myeloid leukaemia by an anti‐programmed death 1 antibody
Sign Up to like & getrecommendations! Published in 2022 at "British Journal of Haematology"
DOI: 10.1111/bjh.18326
Abstract: Nucleophosmin1 (NPM1) is one of the most commonly mutated genes in AML and is often associated with a favourable prognosis. Immune responses play an increasing role in AML treatment decisions; however, the role of immune… read more here.
Keywords: specific immune; immune responses; programmed death; anti ... See more keywords
Activation of central/effector memory T cells and T‐helper 1 polarization in malignant melanoma patients treated with anti‐programmed death‐1 antibody
Sign Up to like & getrecommendations! Published in 2018 at "Cancer Science"
DOI: 10.1111/cas.13758
Abstract: Human anti‐programmed death‐1 (PD‐1) antibody possesses the capability to revitalize host T cells and has been an effective therapy for metastatic malignant melanoma (MM). The precise subsets of T cells predominantly activated by anti‐PD‐1, however,… read more here.
Keywords: programmed death; anti programmed; malignant melanoma; therapy ... See more keywords
NLRP4 negatively regulates type I interferon response and influences the outcome in anti‐programmed cell death protein (PD)‐1/PD‐ligand 1 therapy
Sign Up to like & getrecommendations! Published in 2021 at "Cancer Science"
DOI: 10.1111/cas.15243
Abstract: The challenge to improve the clinical efficacy and enlarge the population that benefits from immune checkpoint inhibitors (ICIs) for non‐small‐cell lung cancer (NSCLC) is significant. Based on whole‐exosome sequencing analysis of biopsies from NSCLC patients… read more here.
Keywords: programmed cell; death protein; cell death; ligand therapy ... See more keywords
Simultaneous development of Graves’ disease and type 1 diabetes during anti‐programmed cell death‐1 therapy: A case report
Sign Up to like & getrecommendations! Published in 2020 at "Journal of Diabetes Investigation"
DOI: 10.1111/jdi.13212
Abstract: We present the first case of simultaneous development of Graves’ disease and type 1 diabetes during anti‐programmed cell death 1 therapy. A 48‐year‐old man with parotid gland adenocarcinoma and lung metastasis had received five courses… read more here.
Keywords: type diabetes; programmed cell; cell death; graves disease ... See more keywords